Search

Search Constraints

You searched for: Author/Creator Abrial, Catherine

Search Results

1. Can pathologic complete response (pCR) be used as a surrogate marker of survival after neoadjuvant therapy for breast cancer?. Issue 1 (July 2015)

2. ERCC1 and telomere status in breast tumours treated with neoadjuvant chemotherapy and their association with patient prognosis. (13th July 2016)

3. Is It Important to Adapt Neoadjuvant Chemotherapy to the Visible Clinical Response? An Open Randomized Phase II Study Comparing Response-Guided and Standard Treatments in HER2-Negative Operable Breast Cancer. (30th January 2015)

4. Is It Important to Adapt Neoadjuvant Chemotherapy to the Visible Clinical Response? An Open Randomized Phase II Study Comparing Response‐Guided and Standard Treatments in HER2‐Negative Operable Breast Cancer. (30th January 2015)

5. Long‐term Significance (15 years) of Pathological Complete Response after Dose‐dense Neoadjuvant Chemotherapy in Breast Cancer. Issue 4 (11th June 2013)

6. Multicenter randomized phase II study comparing docetaxel plus curcumin versus docetaxel plus placebo in first‐line treatment of metastatic castration‐resistant prostate cancer. (5th March 2021)

7. PERCEPTION Trial protocol: Comparison of predictive and prognostic capacities of neutrophil, lymphocyte, and platelet counts and tumor-infiltrating lymphocytes in triple negative breast cancer. Issue 50 (11th December 2020)